Literature DB >> 6683173

Reliability of steroid hormone receptor assays: an international study.

V C Jordan, D T Zava, U Eppenburger, A Kiser, S Sebek, E Dowdle, Z Krozowski, R C Bennett, J Funder, I M Holdaway, J L Wittliff.   

Abstract

The reproducibility of oestrogen and progestin receptor assays performed by laboratories participating in an international breast cancer treatment trial has been assessed. Three tissue reference powders containing low, medium and high oestrogen receptor levels (22 +/- 4, 88 +/- 7, 227 +/- 13 fmol/mg cytosol protein respectively) were prepared in Louisville, KY, U.S.A., assayed repeatedly and multiple samples of each shipped on solid CO2 to the coordination-distribution centre in Berne, Switzerland. Samples were dispatched from Berne to Cantons within Switzerland, to Yugoslavia, South Africa, Australia, New Zealand and also back to the United States for oestrogen and progestin receptor assays. Results were returned to Berne, Switzerland. There was a decrease in the levels of oestrogen and progestin receptors during the time of storage and transit. However, the ability to assign a powder to either the low, medium or high level of oestrogen receptor was not affected. Laboratories also determined progestin receptor. All laboratories clearly identified the powder containing the low level of progestin receptor, but there was poor quantitation with the other two assay standards. It is recommended that clinical hormone receptor laboratories, especially those participating in clinical trials, establish regular quality control procedures for both daily evaluation internally and periodic outside monitoring of interlaboratory variation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6683173     DOI: 10.1016/0277-5379(83)90133-5

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  8 in total

1.  Quality control in immunocytochemistry: experiences with the oestrogen receptor assay.

Authors:  F T Bosman; A F de Goeij; M Rousch
Journal:  J Clin Pathol       Date:  1992-02       Impact factor: 3.411

Review 2.  Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer.

Authors:  V Craig Jordan
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

3.  Steroid receptors in breast cancer: sources of inter-laboratory variation in dextran-charcoal assays.

Authors:  S M Thorpe
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

4.  Quality control of oestrogen receptor assays using frozen breast tumours.

Authors:  S Y Wong; G King; B Angus; A Tesdale; R A Hawkins
Journal:  J Clin Pathol       Date:  1986-06       Impact factor: 3.411

5.  Quantification of oestrogen receptors in breast cancer: radiochemical assay on cytosols and cryostat sections compared with semiquantitative immunocytochemical analysis.

Authors:  H M Scheres; A F De Goeij; M J Rousch; G G Hondius; D D Willebrand; A H Gijzen; F T Bosman
Journal:  J Clin Pathol       Date:  1988-06       Impact factor: 3.411

6.  Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.

Authors:  Marco Colleoni; Zhuoxin Sun; Karen N Price; Per Karlsson; John F Forbes; Beat Thürlimann; Lorenzo Gianni; Monica Castiglione; Richard D Gelber; Alan S Coates; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2016-01-19       Impact factor: 44.544

7.  Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century.

Authors:  Olivia Pagani; Karen N Price; Richard D Gelber; Monica Castiglione-Gertsch; Stig B Holmberg; Jurij Lindtner; Beat Thürlimann; John Collins; Martin F Fey; Alan S Coates; Aron Goldhirsch
Journal:  Breast Cancer Res Treat       Date:  2009-01-10       Impact factor: 4.872

8.  Prognostic value of continuous variables in breast cancer and head and neck cancer. Dependence on the cut-off level.

Authors:  A Courdi; M Héry; P Chauvel; J Gioanni; M Namer; F Demard
Journal:  Br J Cancer       Date:  1988-07       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.